Research programme: kidney disease therapeutics - AstraZeneca/Evotec AG
Latest Information Update: 24 Oct 2013
At a glance
- Originator Evotec AG
- Developer AstraZeneca; Evotec AG
- Mechanism of Action
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Research Kidney disorders
Most Recent Events
- 21 Oct 2013 Early research in Kidney disorders in Germany (unspecified route)